Page 4 - Les meilleurs doctors traitant la maladie suivante : Cancer de l'oesophage - TOP -134 des médecins

Le professeur agrégé Tahsin Ozatli est spécialisé dans les cancers du sein, du poumon et gastro-intestinaux à l'hôpital universitaire Istinye Liv.

• Plus de 10 ans d'expérience en oncologie
• Spécialisation dans les cancers gastro-intestinaux, y compris le cancer de l'œsophage
• Promotion au grade de professeur agrégé en 2016
• Formation à la faculté de médecine de l'université de Selçuk

Le Dr Muzaffer Al est spécialisé dans la chirurgie laparoscopique avancée et oncologique, avec une formation approfondie dans les meilleures institutions médicales.

• Être formé en chirurgie laparoscopique à la faculté de médecine Çapa de l'Université d'Istanbul
• Être spécialisé en chirurgie laparoscopique antireflux et en chirurgie bariatrique laparoscopique avancée
• Avoir de l'expérience en chirurgie oncologique, y compris le cancer de l'œsophage

Le professeur Gul Alco est spécialisé en radio-oncologie avec plus de 20 ans d'expérience, exerçant actuellement à l'Université Medipol d'Istanbul.

• Formée à l'Université d'Istanbul et à l'Université Kadir Has
• Professeur agrégé puis Professeur à l'Université Demiroglu Bilim
• Experte en radio-oncologie pour le traitement du cancer
• Travaille à l'hôpital de district Medipol Acibadem

Le professeur associé Nail Paksoy est spécialisé dans le traitement du cancer de l'œsophage à l'hôpital Medipol Bahçelievler, avec une vaste expérience en recherche et en essais cliniques.

• Certifié par l'ESMO en oncologie médicale
• Participation à 8 essais cliniques internationaux pour divers cancers
• Publication de plusieurs études sur les résultats des traitements contre le cancer
• Formation spécialisée à l'Institut d'oncologie de l'Université d'Istanbul

Plus de 30 ans d'expérience en immunologie avec une spécialisation en virothérapie – Le Dr Jaunalksne apporte son expertise de pointe en immunothérapie au traitement du cancer de l'œsophage.

• Se spécialiser en virothérapie, une approche novatrice du traitement du cancer
• Diriger le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Être diplômé de l'Institut médical de Riga

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Le Dr Auala Hubert dirige le centre des cancers gastro-intestinaux du centre médical Hadassah, apportant 33 ans d'expertise ciblée en oncologie.

• Se spécialiser en oncologie médicale et en radiothérapie pour le cancer de l'œsophage
• Diriger le centre des cancers gastro-intestinaux de l'hôpital universitaire Hadassah
• Certification en oncologie et radiothérapie avec qualifications USMLE
• Membre actif de la Société israélienne d'oncologie clinique et de l'Association contre le cancer

Le Dr Ozden est spécialisé dans le traitement du cancer de l'œsophage et possède une vaste formation en oncologie médicale.

• Diplômé de la faculté de médecine Cerrahpaşa de l'université d'Istanbul
• Spécialisation en oncologie médicale à l'université de Kocaeli
• Plus de dix ans d'expérience en médecine interne et en oncologie
• Exerce à l'hôpital VM Medical Park Pendik

Le Dr Alemdar est spécialisé dans le traitement du cancer de l'œsophage, avec une formation approfondie à l'hôpital universitaire d'Akdeniz – un centre d'oncologie majeur.

• Certifié en oncologie médicale depuis 2018
• Plus de 12 ans d'expérience en oncologie médicale
• Membre de la Société Turque d'Oncologie Médicale
• Exerce au complexe hospitalier Medical Park Antalya – un établissement accrédité par la JCI

Directeur de la résidence en chirurgie au centre médical Hadassah, formant la prochaine génération de chirurgiens à des procédures complexes. Il est maître de conférences en chirurgie depuis près de deux décennies.

• Plus de 35 ans d'expérience en chirurgie et dans les spécialités colorectal
• Instructeur en chirurgie dans un grand hôpital universitaire depuis 1995
• Certifié en chirurgie générale depuis 1998
• Membre actif de plusieurs associations chirurgicales
• Maîtrise de l'anglais et de l'hébreu pour les patients internationaux

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.